Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
CP 263114
Known as:
CP 263,114
, CP-263,114
, CP-263114
National Institutes of Health
Create Alert
Related topics
Related topics
2 relations
Broader (2)
Maleic Anhydrides
phomoidride B
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2002
Highly Cited
2002
Total synthesis of the CP-molecules (CP-263,114 and CP-225,917, phomoidrides B and A). 2. Model studies for the construction of key structural elements and first-generation strategy.
K. Nicolaou
,
P. Baran
,
Y-L Zhong
,
Kin Chiu Fong
,
H. Choi
Journal of the American Chemical Society
2002
Corpus ID: 30160929
Crucial model synthetic and mechanistic studies directed toward the development of methodology for the construction of the maleic…
Expand
2002
2002
Total synthesis of the CP-molecules (CP-263,114 and CP-225,917, phomoidrides B and A). 1. Racemic and asymmetric synthesis of bicyclo[4.3.1] key building blocks.
K. Nicolaou
,
J. Jung
,
+5 authors
P. Baran
Journal of the American Chemical Society
2002
Corpus ID: 12282084
A brief introduction into the chemistry of the CP-molecules is followed by first-generation synthetic sequences toward key…
Expand
2001
2001
Evolution of a synthetic approach to CP-263,114.
J. T. Njardarson
,
J. L. Wood
Organic letters
2001
Corpus ID: 45876338
[structure: see text] Three different approaches to the carbocyclic core of CP-263,114 are presented that illustrate a strategic…
Expand
2001
2001
Application of Lewis acid catalyzed tropone [6+4] cycloadditions to the synthesis of the core of CP-225,917.
L. Isakovic
,
J. A. Ashenhurst
,
J. Gleason
Organic letters
2001
Corpus ID: 24597704
The carbocyclic core of CP-225,917 and CP-263,114 is accessible through the [6+4] cycloaddition of a tropone with a 2-substituted…
Expand
2000
2000
Investigations into a biomimetic approach toward CP-225,917 and CP-263,114.
G. Sulikowski
,
F. Agnelli
,
R. M. Corbett
The Journal of organic chemistry
2000
Corpus ID: 11764933
A biosynthesis of the structurally complex nonadride CP-225,917 (1) is outlined. A key step in this proposal is the dimerization…
Expand
2000
2000
An exploratory study of type II [3 + 4] cycloadditions between vinylcarbenoids and dienes.
H. Davies
,
R. L. Calvo
,
R. Townsend
,
P. Ren
,
R. M. Churchill
The Journal of organic chemistry
2000
Corpus ID: 21808730
The intramolecular type II [3 + 4] cycloaddition between vinylcarbenoids and furans is a practical method for the construction of…
Expand
Highly Cited
1999
Highly Cited
1999
Total Synthesis of the CP Molecules CP-225,917 and CP-263,114- Part 2: Evolution of the Final Strategy.
K. Nicolaou
,
P. Baran
,
+4 authors
H. Choi
Angewandte Chemie
1999
Corpus ID: 13973804
Highly Cited
1999
Highly Cited
1999
Total Synthesis of the CP Molecules CP-263,114 and CP-225,917- Part 1: Synthesis of Key Intermediates and Intelligence Gathering.
K. Nicolaou
,
P. Baran
,
+4 authors
Kin Chiu Fong
Angewandte Chemie
1999
Corpus ID: 14021220
A synthetic labyrinth endowed with countless obstacles, yet filled with numerous hidden treasures, had to be overcome to reach…
Expand
1998
1998
Stereospecific Synthesis of the CP-263,114 Core Structure
C. Chen
,
M. E. Layton
,
M. D. Shair
1998
Corpus ID: 94380182
CP-263,114 (1) is a fungal metabolite that was isolated1,2 as part of a program to identify inhibitors of Ras…
Expand
Highly Cited
1997
Highly Cited
1997
CP-225,917 and CP-263,114, novel Ras farnesylation inhibitors from an unidentified fungus. I. Taxonomy, fermentation, isolation, and biochemical properties.
T. T. Dabrah
,
H. Harwood
,
+8 authors
P. Watts
The Journal of antibiotics
1997
Corpus ID: 8275981
During the course of our screening for squalene synthase inhibitors and Ras farnesylation inhibitors, a novel fungal culture was…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE